Neuraltus Pharmaceuticals just announced that they have appointed a new President and Chief Executive Officer, Richard L. Casey. Casey will replace John Walker, who has been acting as Neuraltus’ interim CEO since September 2012. Late last year Neuraltus announced the results from their Phase II clinical trial of NP001 in people with ALS. Although the results of the study did not reach statistical significance, the study hinted at an effect in a subset of patients. Casey is dedicated to advancing NP001 as a potential treatment for ALS patients. Casey said “Neuraltus’ focus will be on conducting additional clinical research to demonstrate how the activity of NP001 can translate into a clear benefit for patients.” Hopefully under Casey’s leadership Neuraltus will be able to move NP001 forward.
Click here to read more.Share this: